Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
SAN FRANCISCO, Feb. 24, 2016 -- California Life Sciences Association (CLSA), the leading voice to drive innovation for California's life sciences sector, today applauded the U.S. Senate's confirmation of Robert Califf, M.D., as the new commissioner of the U.S. Food and Drug Administration (FDA). CLSA is the nation's largest statewide life sciences public policy, advocacy and business solutions organization serving more than 750 life sciences organizations across California.
Today's confirmation underscores the overall importance and impact of California's life sciences ecosystem. The FDA plays a vital role in the medical technology and biopharmaceutical innovation ecosystem that helps drive California's economy, and delivers life-changing medicines and technologies that benefit health and well-being far beyond the state of California.
"California Life Sciences Association applauds the confirmation of Robert Califf, M.D., as FDA Commissioner. We believe Dr. Califf will be an exemplary steward of the FDA's public health and safety mission, and will continue to improve the agency's drug and device approval processes to ensure that patients receive the safest and most effective treatments as quickly as possible," said Sara Radcliffe, President and CEO, California Life Sciences Association (CLSA). "Dr. Califf has also committed to better incorporating patient and consumer feedback into the regulatory process, and expanding technological capabilities to engage more patients and caregivers to better inform product safety and technology development."
"On behalf of the more than 750 life sciences organizations we represent, California Life Sciences Association strongly supports this confirmation, and we look forward to continuing our collaboration with the FDA and Dr. Califf to meet our shared goals," added Radcliffe.
Dr. Califf previously served as the FDA's Deputy Commissioner for Medical Products and Tobacco, a position he held since March. Prior to joining FDA, Dr. Califf had been with his alma mater, Duke University, since 1982, serving as a professor and vice chancellor at the Duke University School of Medicine, and as director of the Duke Translational Medicine Institute. Dr. Califf also has served as an advisor on the Institute of Medicine of the National Academies (IOM), and as a member of several FDA advisory committees.
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the leading voice for California's life sciences sector. We work closely with industry, government, academia and other stakeholders to shape public policy, drive business solutions and grow California's life sciences innovation ecosystem. CLSA serves over 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged to create the state's most influential life sciences advocacy and business leadership organization. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.
CONTACT: Will Zasadny
Associate Director, Communications
[email protected]
619-961-8848
